Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Gains Phase III Candidate For Treatment Of Opioid Side Effects From Progenics

This article was originally published in The Pink Sheet Daily

Executive Summary

The $60 mil. deal gives Wyeth rights to three different dosage forms of methylnaltrexone for a range of opioid-induced conditions.

You may also be interested in...



First Roche, Then Bristol: Who’s Next?

This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.

First Roche, Then Bristol: Who’s Next?

This first article in a series takes an in-depth look at which pharma/biotech partnerships have the right chemistry to morph from collaboration to merger/acquisition.

Wyeth/Progenics File Methylnaltrexone Injection NDA For Opioid-Induced Constipation

Companies will meet with FDA in May to discuss new study for an oral formulation, Wyeth tells “The Pink Sheet” DAILY.

Related Content

Topics

UsernamePublicRestriction

Register

IV001392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel